alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 105th Congress]
[From the U.S. Government Publishing Office]
[S. 1349 Engrossed in Senate (ES)]

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
105th CONGRESS
  1st Session
                                S. 1349

_______________________________________________________________________

                                 AN ACT

 
To authorize the Secretary of Transportation to issue a certificate of 
   documentation with appropriate endorsement for employment in the 
  coastwise trade for the vessel PRINCE NOVA, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DOCUMENTATION OF THE VESSEL PRINCE NOVA.

    (a) Documentation Authorized.--Notwithstanding section 27 of the 
Merchant Marine Act, 1920 (46 U.S.C. App. 883), section 8 of the Act of 
June 19, 1886 (24 Stat. 81, chapter 421; 46 U.S.C. App. 289), and 
section 12106 of title 46, United States Code, the Secretary of 
Transportation may issue a certificate of documentation with 
appropriate endorsement for employment in the coastwise trade for the 
vessel PRINCE NOVA (Canadian registration number 320804).
    (b) Expiration of Certificate.--A certificate of documentation 
issued for the vessel under subsection (a) shall expire unless--
            (1) the vessel undergoes conversion, reconstruction, 
        repair, rebuilding, or retrofitting in a shipyard located in 
        the United States;
            (2) the cost of that conversion, reconstruction, repair, 
        rebuilding, or retrofitting is not less than the greater of--
                    (A) 3 times the purchase value of the vessel before 
                the conversion, reconstruction, repair, rebuilding, or 
                retrofitting; or
                    (B) $4,200,000; and
            (3) not less than an average of $1,000,000 is spent 
        annually in a shipyard located in the United States for 
        conversion, reconstruction, repair, rebuilding, or retrofitting 
        of the vessel until the total amount of the cost required under 
        paragraph (2) is spent.

            Passed the Senate November 13, 1997.

            Attest:

                                                             Secretary.
105th CONGRESS

  1st Session

                                S. 1349

_______________________________________________________________________

                                 AN ACT

To authorize the Secretary of Transportation to issue a certificate of 
   documentation with appropriate endorsement for employment in the 
  coastwise trade for the vessel PRINCE NOVA, and for other purposes.
```
ex10_2.htm


     

    
      

      

    

    Exhibit 10.2

     

    WAIVER
FORM


    In
consideration for the benefits I will receive as a result of my employer’s
participation in the United States Department of the Treasury’s TARP Capital
Purchase Program, I hereby voluntarily waive any claim against the United States
or my employer for any changes to my compensation or benefits that are required
to comply with the regulation issued by the Department of the Treasury as
published in the Federal Register on October 20, 2008.

     

    I
acknowledge that this regulation may require modification of the compensation,
bonus, incentive and other benefit plans, arrangements, policies and agreements
(including so-called “golden parachute” agreements) that I have with my employer
or in which I participate as they relate to the period the United States holds
any equity or debt securities of my employer acquired through the TARP Capital
Purchase Program.

     

     

    This waiver includes all claims I may
have under the laws of the United States or any state related to the
requirements imposed by the aforementioned regulation, including without
limitation a claim for any compensation or other payments I would otherwise
receive, any challenge to the process by which this regulation was adopted and
any tort or constitutional claim about the effect of these regulations on my
employment relationship.

     

    IN WITNESS WHEREOF, I, intending to be legally
bound hereby, and for full consideration, have executed this Waiver this 21st
day of November, 2008.

    


     

                                                    By:__________________
**EXHIBIT 31.1**
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
I, Katherine D. Crothall, President and Chief Executive Officer of AnimasCorporation, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Animas Corporation;
2. Based on my knowledge, this report does not contain any untrue statement ofa material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements weremade, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of AnimasCorporation as of, and for, the periods presented in this report;
4. Animas Corporation’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a) designed such disclosure controls and procedures, orcaused such disclosure controls and procedures to be designedunder our supervision, to ensure that material informationrelating to Animas Corporation, including its consolidatedsubsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report isbeing prepared; (b) evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in this reportour conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered bythis report based on such evaluation; and (c) disclosed in this report any change in theregistrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter thathas materially affected, or is reasonably likely to materiallyaffect, the registrant’s internal control over financialreporting;
5. Animas Corporation’s other certifying officer and I have disclosed, based onour most recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’s board ofdirectors:
(a) all significant deficiencies and material weaknessesin the design or operation of internal control over financialreporting which are reasonable likely to adversely affect AnimasCorporation’s ability to record, process, summarize and reportfinancial information; and (b) any fraud, whether material or not material, thatinvolves management or other employees who have a significantrole in the registrant’s internal control over financialreporting.
Date: November 15, 2004      By:     /s/ Katherine D. Crothall      Katherine D. Crothall   President and Chief Executive Officer
```

[Congressional Bills 105th Congress]
[From the U.S. Government Publishing Office]
[S. 1319 Introduced in Senate (IS)]

105th CONGRESS
  1st Session
                                S. 1319

               To repeal the Line Item Veto Act of 1996.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 24, 1997

Mr. Byrd (for himself and Mr. Moynihan) introduced the following bill; 
  which was read twice and referred jointly pursuant to the order of 
  August 4, 1977, as modified by the order of April 11, 1986, to the 
 Committees on the Budget and Governmental Affairs, with instructions 
that if one Committee reports, the other Committee have thirty days to 
                        report or be discharged

_______________________________________________________________________

                                 A BILL

 
               To repeal the Line Item Veto Act of 1996.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. REPEAL OF THE LINE ITEM VETO ACT OF 1996.

    (a) In General.--The Line Item Veto Act (Public Law 104-130) and 
the amendments made by that Act are repealed.
    (b) Applicability.--The Impoundment Control Act of 1974 shall be 
applied and administered as if the Line Item Veto Act had not been 
enacted.
                                 <all>
```
Document

Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED.


AMENDMENT #4 TO CO-PROMOTION AGREEMENT 


As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline TRxU for April through June (3th Quarter) of 2021, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS/Anthem data for the zip codes covered by Exagen sale representatives as of April 1, 2021, inclusive of the additional zip codes added.
The parties have agreed that the following sections of the Agreement are hereby amended as follows effective as the date of this notice:


																											
	2.3.4.		The terms of the Promotion Fee shall be adjusted for the quarter ending June 30, 2021 as follows:
									
			2.3.4.1		The Promotion Fee shall be based on a unit value for each quarter over Baseline TRxU, allocated as follows:
									
						For the Quantities	Promotion Fee per unit		
						[***]	[***]		
						[***]	[***]		
						[***]	[***]		
									
						Tiered Baseline			
						[***]			
									
					A minimum payout of $300,000 for Q1 and Q2 of 2021 will be in effect.
									
			2.3.4.2		Unit quantities below Baseline TRxU in a quarter will be counted as zero for purposes of calculating Quantities for Promotion Fee per unit.
									
			2.3.4.3		Janssen will pay Exagen a Minimum Promotion Fee of $300,000 for each of the quarters ending March 31, 2021 and June 30, 2021
									
			2.3.4.4		In addition, the Promotion Fee will be capped at an amount reflecting the payment due in the event that Exagen's TRxU exceeds 10% above the Baseline TRxU for the quarter ending June 30, 2021.
									
					For example:
					[***]				
									
	2.3.5		For the remaining quarters of the Contract Term Extension (July 1, 2021 – December 31, 2021) and any additional Third Term, the Promotion Fee payment terms shall revert to the terms set forth in the Co-Promotion Agreement, with no Minimum Promotion Fee and no Cap (Section 2.3.3).


									
			
	***	Certain Confidential Information Omitted




















In accordance with Amendment #2 dated June 18th, 2020 to the Agreement, please find the Second Term Baseline TRxU for the First Half of 2021:


												
			Quarter ending	Baseline TRxU
			March 31, 2021	[***]
			June 30, 2021	[***]




Please indicate your acceptance by signing the space provided below and returning to Janssen.


									
	JANSSEN BIOTECH, INC.		
	By: /s/ Howard Reid		
	Name: Howard Reid		
	Title: Director of Marketing		
	Date: Jul 27, 2021		
			
	Accepted and agreed		
	As of the date set forth above:		
	By: /s/ Mark Hazeltine		
	Name: Mark Hazeltine		
	Title: COO		
	Date: Jul 9, 2021		








									
			
	***	Certain Confidential Information Omitted
**EXHIBIT 31.2****CERTIFICATIONS**I, Daniel Knutson, certify that:     1. I have reviewed this quarterly report on Form 10-Q of Land O’Lakes, Inc.;     2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;     3. Based on my knowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;     4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and we have:     a) designed such disclosure controls and procedures, or caused such disclosure controlsand procedures to be designed under our supervision, to ensure that material informationrelating to the registrant, including its consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which this report is beingprepared;     b) evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and     c) disclosed in this report any change in the registrant’s internal control over financialreporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during theregistrant’s most recent fiscal quarter that has materially affected, or is reasonably likelyto materially affect, the registrant’s internal control over financial reporting.     5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of registrant’s board of directors:     a) all significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financial information; and     b) any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.Date: August 14, 2007       By: /s/ Daniel Knutson Daniel Knutson    Senior Vice President and    Chief Financial Officer
**EXHIBIT 32.1**

 

**BEA SYSTEMS, INC.**

 

**Certification Pursuant to 18 U.S.C. Section 1350, as Adopted**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

 

In connection with the periodic report of BEA Systems, Inc. (the “Company”) on Form 10-Q for the period ended October 31, 2004 as filed with the Securities and Exchange Commission (the “Report”),I, Alfred S. Chuang, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge: 

 

(1) the Report fully complies with the requirements of Section 13(a) or15(d), as applicable, of the Securities Exchange Act of 1934, and 

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. 

 

This Certification has not been, and shall not be deemed, filed with the Securities ExchangeCommission. 

 

Date: December 9, 2004
II

105TH CONGRESS

1ST SESSION S. 1240

To suspend temporarily the duty on phenmedipham.

IN THE SENATE OF THE UNITED STATES

SEPTEMBER 30, 1997

Mr. ABRAHAM introduced the following bill; which was read twice and referred

to the Committee on Finance

A BILL

To suspend temporarily the duty on phenmedipham.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. TEMPORARY SUSPENSION OF DUTY.

4 (a) IN GENERAL.—Subchapter II of chapter 99 of

5 the Harmonized Tariff Schedule of the United States is

6 amended by inserting in numerical sequence the following

7 new heading:

‘‘ 9902.31.12 3-methylcarbonylaminophenyl-3-

methylcarbanilate

(phenmedipham)

(CAS No.

13684–63–4)

(provided for in

subheading

2924.29.47) ....... Free No change No change On or before

12/31/99 ’’.
2

•S 1240 IS

1 (b) EFFECTIVE DATE.—The amendment made by

2 this section applies with respect to goods entered, or with3 drawn from warehouse for consumption, on or after the

4 15th day after the date of enactment of this Act.

Æ
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Crop Genetics and Breeding Research: Tifton, GA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Southeast Biomass Research Center
                    Forage & Turf ResearchSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Southeast Area Tifton, Georgia Crop Genetics and Breeding Research People & Locations







Jason  Golden
                        Crop Genetics and Breeding Research

                        




                        
                        Agricultural Science Research Technician
                        Phone: (229) 386-7253
                        
                        
                        Fax: (Employee information on this page comes from the REE Directory. Please contact your front office staff to update the REE Directory.)


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Cell Wall Biology and Utilization Research: Madison, WI
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    CareersSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Midwest Area Madison, Wisconsin U.S. Dairy Forage Research Center Cell Wall Biology and Utilization Research People & Locations





- Find a person
- Find a location
- ARS Organizational Chart
- People

People and Locations at Madison, Wisconsin   [Expand All] [Collapse All]
  (Employee information on this page comes from the REE Directory. Please contact your front office staff to update the REE Directory.)


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
<TABLE> <S> <C>

<ARTICLE>           5
<LEGEND>
This schedule contains summary financial information extracted from the
consolidated statements of financial condition and the consolidated statements
of operation of Unified Holdings, Inc. filed as a part of the Company's
quarterly report on Form 10-QSB and is qualified in its entirety by reference
to such report.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                         426,215
<SECURITIES>                                   380,955
<RECEIVABLES>                                1,002,366
<ALLOWANCES>                                     2,041
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,934,925
<PP&E>                                       1,390,849
<DEPRECIATION>                                 879,583
<TOTAL-ASSETS>                               2,902,746
<CURRENT-LIABILITIES>                          969,413
<BONDS>                                              0
<COMMON>                                         1,599
<PREFERRED-MANDATORY>                           17,069
<PREFERRED>                                          0
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 2,902,746
<SALES>                                              0
<TOTAL-REVENUES>                             7,035,722
<CGS>                                                0
<TOTAL-COSTS>                                1,860,694
<OTHER-EXPENSES>                             4,320,156
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,993
<INCOME-PRETAX>                                748,455
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            748,455
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   748,455
<EPS-PRIMARY>                                     1.20
<EPS-DILUTED>                                     0.65
        

</TABLE>